About Exelixis (NASDAQ:EXEL)
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXEL
- CUSIP: 30161Q10
- Web: www.exelixis.com
- Market Cap: $7.99 billion
- Outstanding Shares: 293,904,000
- 50 Day Moving Avg: $26.26
- 200 Day Moving Avg: $24.14
- 52 Week Range: $10.04 - $32.50
Sales & Book Value:
- Trailing P/E Ratio: 137.22
- Foreward P/E Ratio: 40.55
- P/E Growth: 2.13
- Annual Revenue: $319.67 million
- Price / Sales: 24.98
- Book Value: $0.51 per share
- Price / Book: 53.27
- EBITDA: $95.32 million
- Net Margins: 17.83%
- Return on Equity: 52.80%
- Return on Assets: 12.84%
- Current Ratio: 4.12%
- Quick Ratio: 4.06%
- Average Volume: 3.82 million shs.
- Beta: 1.91
- Short Ratio: 4.61
Frequently Asked Questions for Exelixis (NASDAQ:EXEL)
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Wednesday, August, 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The company earned $99.01 million during the quarter, compared to analyst estimates of $85.27 million. Exelixis had a net margin of 17.83% and a return on equity of 52.80%. The firm's quarterly revenue was up 173.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.15) earnings per share. View Exelixis' Earnings History.
When will Exelixis make its next earnings announcement?
Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?
12 brokers have issued 12 month target prices for Exelixis' shares. Their predictions range from $26.00 to $39.00. On average, they expect Exelixis' stock price to reach $31.29 in the next year. View Analyst Ratings for Exelixis.
What are analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. According to Zacks Investment Research, "Exelixis received a significant boost with the approval of the tablet formulation of cabozantinib, (distinct from the capsule form) under the brand name Cabometyx for the treatment of RCC in patients. New patient starts, refills for patients already on therapy and continued expansion of the prescriber base for Cabometyx are driving the drug’s sales. Meanwhile, Exelixis is developing cabozantinib in a broad development program and hassubmitted a supplemental New Drug Application (sNDA) for advanced RCC. The FDA assigned a PDUFA action date of Feb 15, 2018. A potential label expansion of Cabometyx will significantly boost the growth prospects. Exelixis also has collaborations with Bristol-Myers and Roche on the development of the drug in combination with immunotherapy agents. Moreover, Exelixis’ share price has outperformed the industry year to date. However, the company is heavily dependent on Cabometyx for growth." (10/18/2017)
- 2. Cann analysts commented, "Exelixis, Inc. announced today that FDA has granted Priority Review of its supplemental New Drug Application (sNDA) for Cabometyx (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC). FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2018. We have modeled that Cabometyx will expand into the front-line RCC setting by 2019, but based on the timing of the PDUFA date for this indication, we now believe it could happen sooner." (10/16/2017)
Are investors shorting Exelixis?
Exelixis saw a increase in short interest in the month of September. As of September 29th, there was short interest totalling 19,986,804 shares, an increase of 8.2% from the September 15th total of 18,464,387 shares. Based on an average daily volume of 3,898,368 shares, the days-to-cover ratio is currently 5.1 days. Currently, 7.1% of the shares of the company are short sold.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Kite Pharma (KITE), Bioverativ (BIVV), bluebird bio (BLUE), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA) and Ultragenyx Pharmaceutical (RARE).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
- Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
- Christopher J. Senner, Chief Financial Officer, Executive Vice President
- Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
- Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
- Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
- Patrick Haley, Senior Vice President - Commercial
- Charles M. Cohen Ph.D., Independent Director
- Carl B. Feldbaum Esq., Independent Director
- Alan M. Garber M.D. Ph.D., Independent Director
Who owns Exelixis stock?
Exelixis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (5.93%), Meeder Asset Management Inc. (0.01%) and Fisher Asset Management LLC (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Who sold Exelixis stock? Who is selling Exelixis stock?
Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Who bought Exelixis stock? Who is buying Exelixis stock?
How do I buy Exelixis stock?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Exelixis stock can currently be purchased for approximately $27.17.
Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Hold Ratings, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$31.29 (15.15% upside)|Consensus Price Target History for Exelixis (NASDAQ:EXEL)
Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/17/2017||Needham & Company LLC||Boost Price Target||Buy||$30.00 -> $33.00||N/A|
|10/17/2017||Royal Bank Of Canada||Boost Price Target||Outperform -> Outperform||$33.00 -> $39.00||N/A|
|10/17/2017||Stifel Nicolaus||Reiterated Rating||Hold||$26.00||N/A|
|10/16/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||N/A|
|10/16/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Hold||N/A|
|10/16/2017||SunTrust Banks, Inc.||Boost Price Target||Buy -> Buy||$32.00 -> $35.00||N/A|
|9/22/2017||Leerink Swann||Downgrade||Outperform -> Market Perform||$34.00 -> $28.00||High|
|8/10/2017||Cowen and Company||Reiterated Rating||Outperform||Medium|
|8/3/2017||Deutsche Bank AG||Downgrade||Buy -> Hold||$26.00 -> $29.00||Medium|
|7/27/2017||William Blair||Reiterated Rating||Outperform||Medium|
|3/16/2017||CIBC||Initiated Coverage||Market Perform -> Market Perform||High|
|9/28/2016||S&P Equity Research||Boost Price Target||$13.41 -> $15.57||N/A|
Earnings History for Exelixis (NASDAQ:EXEL)Earnings History by Quarter for Exelixis (NASDAQ EXEL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$0.04||$0.06||$85.27 million||$99.01 million||View||Listen|
|5/1/2017||Q1 2017||($0.01)||$0.05||$65.23 million||$80.90 million||View||Listen|
|2/27/2017||Q416||($0.01)||$0.12||$64.88 million||$77.58 million||View||Listen|
|11/3/2016||Q316||($0.13)||($0.04)||$43.15 million||$62.19 million||View||N/A|
|8/3/2016||Q216||($0.27)||($0.16)||$16.76 million||$36.25 million||View||Listen|
|5/4/2016||Q116||($0.25)||($0.27)||$9.11 million||$15.40 million||View||Listen|
|2/29/2016||Q415||($0.22)||($0.19)||$8.16 million||$9.94 million||View||Listen|
|11/10/2015||Q315||($0.20)||($0.22)||$9.08 million||$9.85 million||View||Listen|
|8/11/2015||Q215||($0.21)||($0.22)||$8.69 million||$8.00 million||View||Listen|
|4/30/2015||Q115||($0.24)||($0.18)||$8.08 million||$9.40 million||View||Listen|
|2/24/2015||Q414||($0.31)||($0.30)||$7.50 million||$7.35 million||View||Listen|
|11/4/2014||Q314||($0.37)||($0.32)||$6.77 million||$6.30 million||View||Listen|
|7/31/2014||Q214||($0.39)||($0.38)||$5.66 million||$6.56 million||View||Listen|
|5/1/2014||Q114||($0.37)||($0.39)||$6.11 million||$4.90 million||View||Listen|
|2/20/2014||Q413||($0.38)||($0.38)||$5.71 million||$4.34 million||View||Listen|
|10/30/2013||Q313||($0.37)||($0.36)||$5.55 million||$5.50 million||View||Listen|
|8/6/2013||Q2 2013||($0.30)||($0.34)||$6.55 million||$11.90 million||View||Listen|
|5/7/2013||Q1 2013||($0.29)||($0.24)||$5.33 million||$9.70 million||View||Listen|
|2/21/2013||Q4 2012||($0.24)||($0.28)||$9.46 million||$7.80 million||View||Listen|
|11/7/2012||Q312||($0.30)||($0.20)||$9.22 million||$13.30 million||View||N/A|
Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.13
2018 EPS Consensus Estimate: $0.59
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.10%Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership Percentage: 79.20%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/28/2017||Gisela Schwab||Insider||Sell||100,000||$23.79||$2,379,000.00|| |
|9/28/2017||Jeffrey Hessekiel||EVP||Sell||27,302||$24.28||$662,892.56|| |
|9/22/2017||Stelios Papadopoulos||Director||Sell||10,000||$25.40||$254,000.00|| |
|9/19/2017||Stelios Papadopoulos||Director||Sell||200,000||$27.68||$5,536,000.00|| |
|9/18/2017||Stelios Papadopoulos||Director||Sell||72,210||$27.76||$2,004,549.60|| |
|9/14/2017||Michael Morrissey||Insider||Sell||300,000||$26.90||$8,070,000.00|| |
|9/14/2017||Patrick J. Haley||VP||Sell||60,640||$27.21||$1,650,014.40|| |
|9/13/2017||Lance Willsey||Director||Sell||100,000||$26.88||$2,688,000.00|| |
|9/12/2017||Christopher J. Senner||CFO||Sell||100,000||$26.79||$2,679,000.00|| |
|5/30/2017||Patrick J. Haley||Insider||Sell||5,000||$18.46||$92,300.00|| |
|5/15/2017||Carl B Feldbaum||Director||Sell||32,988||$21.58||$711,881.04|| |
|5/10/2017||Michael Morrissey||Insider||Sell||211,300||$21.87||$4,621,131.00|| |
|5/9/2017||Michael Morrissey||CEO||Sell||100,000||$21.69||$2,169,000.00|| |
|5/8/2017||Michael Morrissey||CEO||Sell||11,300||$21.81||$246,453.00|| |
|5/5/2017||Michael Morrissey||Insider||Sell||259,149||$22.24||$5,763,473.76|| |
|5/1/2017||Gisela Schwab||CMO||Sell||89,910||$23.01||$2,068,829.10|| |
|4/3/2017||Vincent T Marchesi||Director||Sell||10,000||$21.30||$213,000.00|| |
|3/31/2017||Jack L Wyszomierski||Director||Sell||5,150||$21.57||$111,085.50|| |
|3/27/2017||Jeffrey Hessekiel||EVP||Sell||6,884||$21.02||$144,701.68|| |
|3/22/2017||Jeffrey Hessekiel||EVP||Sell||23,787||$20.54||$488,584.98|| |
|3/20/2017||Stelios Papadopoulos||Director||Sell||10,000||$21.66||$216,600.00|| |
|3/13/2017||Charles Cohen||Director||Sell||10,000||$21.82||$218,200.00|| |
|3/10/2017||Vincent T Marchesi||Director||Sell||40,000||$21.98||$879,200.00|| |
|3/6/2017||Michael Morrissey||Insider||Sell||200,000||$22.72||$4,544,000.00|| |
|3/3/2017||Christopher J. Senner||CFO||Sell||11,000||$22.80||$250,800.00|| |
|3/2/2017||George Poste||Director||Sell||76,250||$22.53||$1,717,912.50|| |
|1/3/2017||Peter Lamb||EVP||Sell||70,000||$14.65||$1,025,500.00|| |
|12/16/2016||Carl B. Feldbaum||Director||Sell||25,000||$17.03||$425,750.00|| |
|12/9/2016||Alan M. Garber||Director||Sell||7,832||$16.90||$132,360.80|| |
|12/7/2016||George A. Scangos||Director||Sell||204,894||$17.81||$3,649,162.14|| |
|12/5/2016||George A. Scangos||Director||Sell||204,718||$17.81||$3,646,027.58|| |
|12/1/2016||Gisela Schwab||Insider||Sell||22,000||$16.73||$368,060.00|| |
|12/1/2016||Peter Lamb||EVP||Sell||70,000||$16.66||$1,166,200.00|| |
|8/4/2016||Gisela Schwab||Insider||Sell||42,338||$11.00||$465,718.00|| |
|5/11/2016||Lance Willsey||Director||Buy||60,000||$4.97||$298,200.00|| |
|5/9/2016||Lance Willsey||Director||Buy||40,000||$4.97||$198,800.00|| |
|12/11/2015||Lance Willsey||Director||Buy||100,000||$4.89||$489,000.00|| |
|10/16/2015||Peter Lamb||EVP||Sell||51,549||$5.80||$298,984.20|| |
|10/13/2015||Peter Lamb||EVP||Sell||600||$5.80||$3,480.00|| |
|10/12/2015||Peter Lamb||EVP||Sell||300,276||$5.84||$1,753,611.84|| |
|9/17/2014||Vincent T Marchesi||Director||Buy||20,000||$1.71||$34,200.00|| |
|8/29/2013||Lance Willsey||Director||Buy||10,000||$5.15||$51,500.00|| |
|12/20/2012||Vincent T Marchesi||Director||Buy||4,000||$4.68||$18,720.00|| |
|12/19/2012||Vincent T Marchesi||Director||Buy||6,000||$4.72||$28,320.00|| |
|12/10/2012||Gisela Schwab||EVP||Buy||25,000||$4.39||$109,750.00|| |
Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Loading headlines, please wait.
Exelixis (EXEL) Chart for Monday, October, 23, 2017